Bpifrance

Leveraging cutting-edge quantum detectors, we design light, portable, and performing MRI machines working at ultra-low magnetic fields for a tenth of current prices.

Fizimed SAS, founded in 2017 and based in Strasbourg, France, specializes in manufacturing a perineal device designed to address urinary incontinence in women through pelvic floor reeducation. The company's flagship product, EMY, is a perineal probe that connects to a mobile app, allowing users to engage in personalized exercises for strengthening pelvic floor muscles. EMY not only captures real-time muscle contractions but also incorporates interactive elements, such as games, to motivate users during their five-minute workouts. Fizimed emphasizes user-friendliness and safety in its product design, aiming to empower women in managing their pelvic health at home. Additionally, the company actively seeks to eliminate the stigma surrounding urinary incontinence, fostering a supportive community on social media where women can share experiences and innovations related to this common health issue. Through its combination of medical efficacy and engaging technology, Fizimed aims to provide women with the tools they need to regain control over their pelvic health in a discreet and enjoyable manner.

SUPERBRANCHE is a biotechnology company focused on the early detection and treatment of metastases using advanced nanotechnology. The company develops therapeutic and diagnostic applications that aim to enhance accessibility and facilitate the timely identification of tumors. Its innovative platform incorporates targeted diagnostic and image-guided therapy nanomaterials, grounded in proprietary technology. This approach enables healthcare providers to detect and address metastases earlier, ultimately improving patient outcomes.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

Okomera is a biotech start-up focused on enhancing the development of precision-based cancer medicines. The company specializes in automating and streamlining individualized tumor biopsy research through innovative medical technologies. By utilizing microfluidic 3D cellular assays, Okomera's approach allows for the prediction of patient-specific responses to therapies. This is achieved by cultivating cells within thousands of microfluidic droplets and exposing them to various conditions in parallel, which accelerates the process of biologically relevant biopsy testing. Consequently, Okomera's technologies enable healthcare providers to expedite cancer treatment, ultimately improving patient outcomes.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

HEPTA Medical is a medical technology company focused on developing a microwave ablation platform for the treatment of early lung cancer. The company's innovative solution includes a microwave ablation catheter equipped with a proprietary temperature sensor, which allows healthcare professionals to monitor and control the ablation volume in real-time. This technology aims to provide a minimally invasive, nonsurgical treatment option, enhancing the efficiency and safety of cancer ablation procedures. By enabling precise control over the size of the lesion being treated, HEPTA Medical seeks to improve patient outcomes in cancer care.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

May Health specializes in developing innovative solutions for infertility related to Polycystic Ovary Syndrome (PCOS). The company offers a minimally invasive procedure aimed at restoring ovulation in women with PCOS, providing a more natural approach to pregnancy. This one-time treatment is performed transvaginally under ultrasound guidance, eliminating the need for general anesthesia. The procedure is designed to assist the body's natural ovulation process and can be conducted in a clinical setting, similar to techniques used by fertility specialists in in vitro fertilization (IVF). May Health's focus is on delivering effective, durable solutions for patients seeking to conceive while minimizing the medicalization of the pregnancy experience.

Pixee Medical is a medical technology company based in Chavanod, France, founded in 2017. The company specializes in the manufacturing of computer-assisted surgical solutions that utilize advanced computer vision and artificial intelligence technologies. Pixee Medical produces medical equipment designed to control the positioning of implants during orthopedic surgeries. Its innovative tracking tools enable precise three-dimensional localization of surgical objects, allowing healthcare professionals to perform procedures with millimeter accuracy. By focusing on affordability, Pixee Medical aims to provide effective surgical navigation solutions that address the challenges of the current healthcare environment.

I.Ceram SA, founded in 2005 and based in Limoges, France, specializes in the design, manufacture, and marketing of alumina bio-ceramic implants. The company produces implants for various joints of the human body, including the ankle, knee, hip, spine, shoulder, wrist, skull, tibia, and foot. In addition to joint implants, I.Ceram also offers osteosynthesis products. As a subsidiary of Investissement Développement, I.Ceram operates both domestically and internationally, focusing on high-tech solutions in the medical implant sector.

Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, that specializes in the design, development, and production of amorphous metal parts. Founded in 2017, Vulkam utilizes biocompatible amorphous metal alloys primarily composed of materials such as zirconium, copper, hafnium, nickel, and titanium. The company's innovative products find applications across various industries, including aerospace, automotive, biomedical, cryogenic, watches, jewellery, and micro components. Vulkam's focus on creating micromechanical parts that are significantly smaller yet maintain strength and functionality sets a new standard in metallurgy and metal processing, positioning the company as a leader in the development of advanced metal technologies.

Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, that specializes in the design, development, and production of amorphous metal parts. Founded in 2017, Vulkam utilizes biocompatible amorphous metal alloys primarily composed of materials such as zirconium, copper, hafnium, nickel, and titanium. The company's innovative products find applications across various industries, including aerospace, automotive, biomedical, cryogenic, watches, jewellery, and micro components. Vulkam's focus on creating micromechanical parts that are significantly smaller yet maintain strength and functionality sets a new standard in metallurgy and metal processing, positioning the company as a leader in the development of advanced metal technologies.

Okomera is a biotech start-up focused on enhancing the development of precision-based cancer medicines. The company specializes in automating and streamlining individualized tumor biopsy research through innovative medical technologies. By utilizing microfluidic 3D cellular assays, Okomera's approach allows for the prediction of patient-specific responses to therapies. This is achieved by cultivating cells within thousands of microfluidic droplets and exposing them to various conditions in parallel, which accelerates the process of biologically relevant biopsy testing. Consequently, Okomera's technologies enable healthcare providers to expedite cancer treatment, ultimately improving patient outcomes.

Callyope is a human-centered technology that can enhance millions of people's lives by increasing the objectivity and responsiveness of brain health monitoring. Callyope develops solutions for remote patient monitoring that assist caregivers in identifying relapses and determining the best course of action.

Injectpower creates energy storage technologies and micro-batteries for medical implants. Its small solid-state battery allows devices to function as sensors or actuators, collecting data continuously and autonomously for weeks without needing to be recharged. Their micro-batteries, which have been developed over 16 years and have 40 patents, are manufactured utilizing a verified semiconductor supply chain and have high reliability.

X-Pressure is a medical device to measure cerebrospinal fluid pressure to better diagnose brain diseases.

SFE PROCESS designs and manufactures lab equipment.

SMAIO is a manufacturer of medical devices for spinal pathologies. They provide control over surgical procedures to the spine physician through a range of solutions.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

Dianosic SAS, founded in 2017 and based in Strasbourg, France, specializes in developing advanced medical devices for Ear, Nose, and Throat (ENT) conditions. The company has created CAVI-T, an innovative intranasal balloon designed to stop spontaneous or postoperative bleeding through low-pressure compression, while also preventing biofilm formation and enhancing healing. Additionally, Dianosic is working on the Active Resorbable Intranasal Scaffold (ARIS), a groundbreaking treatment for chronic sinusitis and allergic rhinitis, which offers a long-lasting drug-eluting solution that can last from six to twelve months. This technology not only addresses patient compliance challenges but also presents opportunities for expanding treatment options in related areas such as chronic migraine and facial pain. Through its cutting-edge solutions, Dianosic aims to redefine standards of care in ENT healthcare.

Orthopus manufactures and distributes medical devices. They develop a range of robotic devices for arm mobility. Their supporter compensates for the weight of the arm to facilitate vertical movements. Their robotic device is used in an electric wheelchair and on a table.

Clarity is a clinical-stage company pioneering a new category of non-pharmacological treatments for neurodegenerative diseases. We develop a neuromodulation device combining immersive technology, AI and biosensors to deliver gamma sensory stimulation. Gamma waves’ sensory stimulation has been shown to significantly slow down Alzheimer's progression, reducing neurodegeneration and cognitive decline. Clarity takes a platform approach by enabling the customization of sensory stimulation protocols based on patient data, improving experience, efficacy and scalability across a wide range of indications. The company was founded by neuroscientists from UC Berkeley, and Oxford along with execs from OURA and Philips, and is supported by leading institutions such as UCSF's Neuroscape.

Remedee Labs SAS is a French company founded in 2016, specializing in the research and development of a personal endorphin stimulator aimed at pain management. The company has created the Microelectronic Endorphin Trigger (MEET), a device designed to stimulate the release of the body’s own endorphins on demand. This innovative technology is particularly focused on helping individuals suffering from chronic pain conditions, with an initial emphasis on fibromyalgia. Remedee Labs has developed a patient-centered digital service platform that collaborates with medical practitioners to enhance chronic pain management. Backed by a decade of pre-clinical and clinical research, the company aims to provide a new approach to pain relief for the 1.5 billion people worldwide affected by chronic pain, many of whom are dissatisfied with existing treatment options. In 2019, Remedee Labs secured significant funding from various investors to further its mission of making endorphin-stimulation therapy accessible and effective for personal healthcare.

Meccellis Biotech SAS, founded in 2013 and based in La Rochelle, France, specializes in developing biologic implants using acellular dermis. The company focuses on tissue and cell engineering to create biological implants that facilitate tissue repair across various surgical specialties. Their product offerings include Cellis and Cellis breast implants, designed to address specific clinical needs during surgical procedures, such as abdominal wall repair. By maintaining continuous communication with surgeons, Meccellis Biotech aims to provide tailored solutions that meet the evolving demands of the medical field.

Guerbet is a human-scale company that aims to become a new global leader in medical imaging. Pioneer in contrast media with 90 years'​ experience, Guerbet is the only pharmaceutical group dedicated to medical imaging worldwide, with a presence in almost 80 countries via a network of subsidiaries and distributors. The company offers a comprehensive range of CT scan, Cath Lab, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostic (IRT) products, along with a range of injectors and related medical devices to improve patients'​ diagnosis, prognosis and quality of life.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Nurea develops a decision-making support solution specifically for healthcare professionals, particularly vascular surgeons. The company specializes in medical imaging software that automates image analysis, providing accurate quantitative assessments to aid in the diagnosis of vascular diseases. Its platform facilitates the management of patient groups during both pre- and post-operative monitoring through an automated workflow, which includes comprehensive full-body scan analysis. By offering decision indicators aimed at preventing cardiovascular incidents, Nurea simplifies the decision-making process for surgeons, enhancing patient care in the realm of cardiovascular health. An online inquiry form is available on their website for further information.

Healshape is a biotech startup dedicated to developing natural breast reconstruction solutions for women. The company specializes in regenerative medicine, focusing on creating innovative alternatives for breast regeneration through advanced 3D bioprinting technology. Healshape's primary product is a bioprosthesis designed for breast reconstruction, which aims to empower women by helping them regain self-confidence and achieve long-lasting, aesthetically pleasing results following surgery.

Hemerion is a biotechnology company dedicated to developing innovative cancer treatments, specifically targeting glioblastoma, the most prevalent and aggressive primary brain tumor. The company operates a platform that integrates therapeutic services at the intersection of surgery and photonics, utilizing a photosensitizing drug for a drug-device combination therapy. This approach enables healthcare professionals to selectively destroy cancer cells in regions that are difficult to access through traditional surgical methods, all while preserving healthy tissues. Hemerion's focus on advanced treatment options aims to enhance the healthcare industry's ability to combat brain cancer and improve patient outcomes in the fight against glioblastoma.

LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.

Cairdac is a medtech startup focused on developing an innovative leadless pacing system that utilizes a self-sustaining power technology. The company has achieved a significant milestone by creating the first self-sustaining pacemaker with a lifespan exceeding 15 years, leveraging a proprietary piezoelectric energy harvester in conjunction with a miniaturized power management circuit. Their unique product, the ALPS, is an autonomous and endoscopically implanted leadless pacemaker designed to harness the heart's kinetic energy for power. By integrating disruptive technologies into traditional pacemaker designs, Cairdac aims to provide a cost-effective solution that addresses the evolving needs of patients and healthcare professionals while enhancing the overall quality of life for those requiring cardiac rhythm management.

VistaCare is a French company specializing in the development, manufacturing, and distribution of medical devices designed for the treatment of acute and chronic wounds. The company focuses on innovative, non-contact treatment methods that operate in a controlled environment. Their technology addresses critical aspects of wound care, including the reduction of nosocomial risks, visual monitoring of wound progression, and tailored medical protocols based on the specific type and stage of each wound. By enhancing the quality of life for patients and streamlining the care process for caregivers, VistaCare aims to significantly reduce treatment times and hospital stays, offering a more effective solution for complex wounds that are challenging to manage with conventional therapies.

Quantum Surgical is a company focused on enhancing the treatment of liver cancer through minimally invasive procedures. They develop surgical robotics that provide intelligent tools for advanced percutaneous ablation therapy, which is designed to improve patient outcomes and safety in interventional oncology. By democratizing access to these innovative treatment options, Quantum Surgical aims to enable healthcare providers to more effectively cure patients and enhance their quality of life.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

Omini is a French company, established in 2019 and based in Saint Mandé, that specializes in the development of portable and multipurpose bio-sensing devices for blood testing. The company’s biosensor platform allows for the simultaneous detection of multiple biomarkers, providing personalized blood biomarker data that can be utilized to tailor therapies and prevent acute crises in patients with chronic conditions. By employing advanced multiplex electrochemical biosensor technology, Omini's devices offer accurate and affordable solutions for identifying, analyzing, and monitoring various target biomarkers. This innovation supports decentralized testing and at-home monitoring, ultimately aiming to alleviate the burden on healthcare systems and improve patient outcomes. Omini primarily serves general practitioners, enhancing their ability to manage patient care effectively.

Grapheal is a Medtech startup focused on developing embedded and wearable biosensors that leverage graphene transistors for enhanced functionality. Their devices are designed to be minimalistic and digital, enabling the dosing of biomarkers and detection of pathogens through a smartphone interface. By integrating advanced sensing nanomaterials with wireless connectivity and data analysis capabilities, Grapheal's biosensors facilitate field diagnostics and remote patient monitoring. This approach aims to make healthcare more accessible and accurate, allowing medical professionals to effectively monitor patient progress and healing.

eCential Robotics specializes in enhancing minimally invasive surgical procedures through advanced imaging technology. The company has developed a system that combines fluoroscopy, surgical navigation, and robotics to improve treatment outcomes across various medical indications. This integrated operating system offers high-definition imaging and real-time navigation, which aids surgeons in performing complex orthopedic and trauma surgeries. By enabling day surgery practices, eCential Robotics provides significant benefits to patients and healthcare providers alike, including reduced radiation exposure, increased safety, and improved accuracy during operations.

Lucine has the ambition to transform and improve patient’s health. Their main therapeutic area is pain. The product, a digital therapeutic is able to relieve patient’s pain in 5 minutes through active substances allowing an analgesic neurostimulation. Customized, their solution is adapted to each patient thanks to an instantaneous measurement and analysis of the pain by facial, vocal and postural recognition.

Multiwave Imaging is a leading company specializing in the design of metamaterial antennas for Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) systems. Established in March 2015 and headquartered in Geneva, Switzerland, with a research and development facility in France, Multiwave focuses on developing innovative medical imaging devices. The company aims to enhance imaging quality in MRI, ultimately aiding in the treatment of neurological conditions. In addition to its core imaging technologies, Multiwave employs advanced quantitative portfolio analysis and sensor technologies to support retailers in their purchasing strategies, thereby maximizing profits. Through these initiatives, Multiwave Imaging seeks to advance the field of medical imaging while addressing critical healthcare needs.

Moon Surgical is a medical device company focused on enhancing laparoscopic surgery through its innovative Maestro System. This system is designed to facilitate access to minimally invasive surgical techniques while optimizing resource utilization in the operating room. By providing features such as stabilization and automatic positioning of endoscopes, along with organ retraction, the Maestro System aims to improve surgical efficiency and patient care. Moon Surgical's technology allows surgeons to maintain their existing workflows and techniques, integrating the advantages of robotic assistance without disrupting traditional practices. Through its commitment to advancing surgical technology, Moon Surgical seeks to transform the landscape of surgery today.

Quantum Surgical is a company focused on enhancing the treatment of liver cancer through minimally invasive procedures. They develop surgical robotics that provide intelligent tools for advanced percutaneous ablation therapy, which is designed to improve patient outcomes and safety in interventional oncology. By democratizing access to these innovative treatment options, Quantum Surgical aims to enable healthcare providers to more effectively cure patients and enhance their quality of life.

Ambler is a startup founded in 2018 by experts in digital and so-called "marketplace" models 100% French, the company enjoys the support of public authorities (Wilco-ex Scientipôle) and the support of prestigious private investors , including Partech, Idinvest Partners, Kima Ventures. The startup is developing technologies to help match the supply and demand of medical transports. It aggregates, thanks to win-win partnerships, a considerable fleet of vehicles and offers unparalleled deliverability for contractors. Ambler is the only solution capable, nationwide, of absorbing the constant growth of health transport flows induced by demographic and regulatory factors (reform of regional hospital groups).

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

Dianosic SAS, founded in 2017 and based in Strasbourg, France, specializes in developing advanced medical devices for Ear, Nose, and Throat (ENT) conditions. The company has created CAVI-T, an innovative intranasal balloon designed to stop spontaneous or postoperative bleeding through low-pressure compression, while also preventing biofilm formation and enhancing healing. Additionally, Dianosic is working on the Active Resorbable Intranasal Scaffold (ARIS), a groundbreaking treatment for chronic sinusitis and allergic rhinitis, which offers a long-lasting drug-eluting solution that can last from six to twelve months. This technology not only addresses patient compliance challenges but also presents opportunities for expanding treatment options in related areas such as chronic migraine and facial pain. Through its cutting-edge solutions, Dianosic aims to redefine standards of care in ENT healthcare.

Multiwave Imaging is a leading company specializing in the design of metamaterial antennas for Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) systems. Established in March 2015 and headquartered in Geneva, Switzerland, with a research and development facility in France, Multiwave focuses on developing innovative medical imaging devices. The company aims to enhance imaging quality in MRI, ultimately aiding in the treatment of neurological conditions. In addition to its core imaging technologies, Multiwave employs advanced quantitative portfolio analysis and sensor technologies to support retailers in their purchasing strategies, thereby maximizing profits. Through these initiatives, Multiwave Imaging seeks to advance the field of medical imaging while addressing critical healthcare needs.

Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, that specializes in the design, development, and production of amorphous metal parts. Founded in 2017, Vulkam utilizes biocompatible amorphous metal alloys primarily composed of materials such as zirconium, copper, hafnium, nickel, and titanium. The company's innovative products find applications across various industries, including aerospace, automotive, biomedical, cryogenic, watches, jewellery, and micro components. Vulkam's focus on creating micromechanical parts that are significantly smaller yet maintain strength and functionality sets a new standard in metallurgy and metal processing, positioning the company as a leader in the development of advanced metal technologies.

Laclarée Vision specializes in the development of adaptive eyeglasses designed to correct presbyopia. Founded in 2016 and based in Lyon, France, the company utilizes patented fluid technology to create lenses that automatically adjust in real-time to various viewing distances. This innovative approach addresses the needs of individuals aged 45 and older who often find traditional solutions, such as progressive lenses or multiple pairs of glasses, unsatisfactory. By combining adaptive lens technology with refractive correction for conditions like astigmatism, myopia, and hyperopia, Laclarée aims to provide a clearer vision experience for its users.

BioSerenity is a company focused on enhancing the understanding and treatment of epilepsy and other chronic diseases through the development of digitally connected devices. These devices facilitate the retrieval and interpretation of electrophysiological signals, including electroencephalograms, electrocardiograms, and polysomnography. By enabling remote monitoring of continuous electrophysiological signals, BioSerenity aims to optimize patient care pathways in cardiology, neurology, and sleep disorders. The data collected from these devices, once anonymized, will be made available to researchers at the Institut du Cerveau et de la Moelle épinière, contributing to advancements in epilepsy research and improving diagnostic methods for the future.

ADDEV Materials SAS, founded in 2006 and based in Lyon, France, specializes in the manufacturing and distribution of high-performance materials, including adhesive tapes, glues, mastics, abrasives, insulation, and technical components. The company serves a variety of industries, such as automotive, aerospace, energy, railway, nuclear, and medical, by transforming and custom cutting various types of insulation and technical films. Additionally, ADDEV Materials provides customized solutions and distribution services for technical adhesives, helping clients address their specific technical challenges effectively.

Neurallys is a Paris-based company specializing in the development and production of medical devices for neurology and neurosurgery. The company has created an intelligent sensor that communicates with a smartphone to monitor intracranial pressure in patients with hydrocephalus. This innovative device aims to enhance patient comfort and provide neurosurgeons with a valuable tool for more effective management and follow-up of the condition, ultimately improving the quality of care for those affected by hydrocephalus.

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

Presto Engineering, Inc. is a provider of outsourced development operations for semiconductor and Internet of Things (IoT) device companies. Founded in 2006 and headquartered in San Jose, California, the company specializes in turn-key solutions that encompass radio-frequency (RF), mixed-signal devices, and comprehensive semiconductor testing and analysis services. Its offerings include wafer fabrication, back-end processing, and various backend packaging services. Additionally, Presto Engineering provides extensive product engineering, debugging, and release acceleration services, which cover testing, reliability assessments, and yield enhancement. The company serves a diverse range of sectors, including medical, automotive, industrial, and communications. With additional offices in France, Thailand, and Taiwan, Presto Engineering aims to help clients minimize overhead, reduce risk, and expedite their time-to-market.

C4Diagnostics specializes in the development and commercialization of in vitro diagnostic (IVD) kits utilizing its proprietary technology. The company focuses on creating medical devices and equipment that enhance the speed and sensitivity of diagnostic tests. One of its primary offerings includes solutions for urinary tract infection screening, which reliably detects, counts, and concentrates culturable microorganisms relevant to clinical microbiology. This capability allows hospitals and laboratories to conduct culture-based IVD tests with improved accuracy and efficiency, contributing to better patient outcomes in diagnostic processes.

LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.

eCential Robotics specializes in enhancing minimally invasive surgical procedures through advanced imaging technology. The company has developed a system that combines fluoroscopy, surgical navigation, and robotics to improve treatment outcomes across various medical indications. This integrated operating system offers high-definition imaging and real-time navigation, which aids surgeons in performing complex orthopedic and trauma surgeries. By enabling day surgery practices, eCential Robotics provides significant benefits to patients and healthcare providers alike, including reduced radiation exposure, increased safety, and improved accuracy during operations.

Fizimed SAS, founded in 2017 and based in Strasbourg, France, specializes in manufacturing a perineal device designed to address urinary incontinence in women through pelvic floor reeducation. The company's flagship product, EMY, is a perineal probe that connects to a mobile app, allowing users to engage in personalized exercises for strengthening pelvic floor muscles. EMY not only captures real-time muscle contractions but also incorporates interactive elements, such as games, to motivate users during their five-minute workouts. Fizimed emphasizes user-friendliness and safety in its product design, aiming to empower women in managing their pelvic health at home. Additionally, the company actively seeks to eliminate the stigma surrounding urinary incontinence, fostering a supportive community on social media where women can share experiences and innovations related to this common health issue. Through its combination of medical efficacy and engaging technology, Fizimed aims to provide women with the tools they need to regain control over their pelvic health in a discreet and enjoyable manner.

BioSerenity is a company focused on enhancing the understanding and treatment of epilepsy and other chronic diseases through the development of digitally connected devices. These devices facilitate the retrieval and interpretation of electrophysiological signals, including electroencephalograms, electrocardiograms, and polysomnography. By enabling remote monitoring of continuous electrophysiological signals, BioSerenity aims to optimize patient care pathways in cardiology, neurology, and sleep disorders. The data collected from these devices, once anonymized, will be made available to researchers at the Institut du Cerveau et de la Moelle épinière, contributing to advancements in epilepsy research and improving diagnostic methods for the future.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

Conscious Labs specializes in developing brain-computer interface (BCI) technology that allows for the collection of research-grade EEG data in real-world settings. The company creates advanced head-wearable devices designed to integrate seamlessly into headphones, earbuds, and VR and AR headsets. This technology enables electronics manufacturers and startups to embed BCI capabilities into their products, facilitating out-of-lab research and enhancing user experiences. Additionally, Conscious Labs offers expertise in sensor development and provides an innovative ionic polymer suitable for biosensors in wearable devices, thereby advancing the capabilities of biosensing technologies.

Biom'Up, expert in the field of resorbable biomaterials, designs, develops and manufactures unique medical devices based on collagen technology. These innovative and clinically proven products cover many different surgical specialties - orthopaedics, spinal, cardiac, general and maxillo-facial - and improve patient healing by allowing guided regeneration of soft tissues and bone.

Lewis Industries specializes in the design and manufacture of precision sheet metal parts, incorporating electronic components as necessary to deliver fully assembled equipment. Founded in 1966 and based in Nemours, France, the company serves various sectors including medical, lighting, information technology, telecommunications, heating, transport, and instrumentation. With over 40 years of experience, Lewis Industries is known for its expertise in high precision operations such as laser cutting, sheet metal bending, welding, assembly, and finishing. The company is committed to providing parts with both simple and complex geometries, as well as functional units tailored to the specific needs of its clients.

Theravectys is a biotechnology company focused on developing a novel vaccine platform aimed at treating and preventing a wide array of infectious diseases, cancers, and other medical conditions. The company’s innovative vaccination technology utilizes gene transfer into dendritic cells to modulate the immune response, enhancing the effectiveness of both prophylactic and therapeutic immunotherapies. Their lead product, a therapeutic vaccine targeting HIV/AIDS, has demonstrated promising efficacy and safety in non-human primate studies and is set to enter clinical trials. Through its diverse pipeline, Theravectys aims to provide healthcare providers with advanced treatment options that elicit a potent and targeted immune response in patients.

ECM Technologies SA engages in the manufacture of industrial furnaces for car, electronics, photovoltaic, laboratory/research, metallurgy, aeronautics/aerospace/maritime, chemistry, nuclear, medical, and ceramics industries.

Santen specializes in the research, development, marketing, and sales of innovative eye care products and services that enable optimal sight. They help physicians address the complex clinical challenges in vision care with novel solutions for glaucoma, retinal diseases, and other eye conditions.

Santen specializes in the research, development, marketing, and sales of innovative eye care products and services that enable optimal sight. They help physicians address the complex clinical challenges in vision care with novel solutions for glaucoma, retinal diseases, and other eye conditions.

Santen specializes in the research, development, marketing, and sales of innovative eye care products and services that enable optimal sight. They help physicians address the complex clinical challenges in vision care with novel solutions for glaucoma, retinal diseases, and other eye conditions.

Santen specializes in the research, development, marketing, and sales of innovative eye care products and services that enable optimal sight. They help physicians address the complex clinical challenges in vision care with novel solutions for glaucoma, retinal diseases, and other eye conditions.

Oxxius is a laser design and manufacturing house founded in 2002 to bring disruptive innovations to the market of visible lasers. We develop advanced continuous-wave laser modules targeting numerous applications in bio-photonics, metrology, spectroscopy and other analytics and instrumentation applications, for both research and industry customers. Oxxius is headquartered in western France and located among a major optics and photonics cluster. Oxxius’ products leverage an innovative, patented solid-state laser architecture offering major advances in compactness, reliability and cost of ownership. In addition, this technology enables exceptional spectral and spatial beam characteristics, as well as market-leading power levels. We also offer a broad range of diode laser modules to cover all the wavelength range from UV to near-infrared. Together with bringing outstanding products to the market, Oxxius is committed to offering a world-class level of quality, customer care and service.